This post was originally published on this site The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care have entered a collaboration with Personalis to use its cancer immunogenomics platform to identify which ovarian cancer patients respond to a new combination therapy — Lynparza (olaparib) plus the investigational…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Being Reborn: My Stem Cell Transplant Journey
This post was originally published on this site It seems like years have passed since I published a column. In reality, it’s been less than two months. But as we know, life can change pretty drastically over the course of a week, let alone a couple of months. I know that mine certainly has, and…
TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception
This post was originally published on this site A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food and Drug Administration, An emergency IND can be used by physicians to request permission to give an investigational…
TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy
This post was originally published on this site TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, in an ongoing Phase 1/2 clinical trial for people with advanced cancers that produce the mesothelin protein. Mesothelin is a protein highly abundant in several solid tumors, including…
Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma
This post was originally published on this site Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a preclinical study shows. The study, “GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed…
Partnership Aims to Identify DLBCL Patients Likely to Benefit from ADCT-402
This post was originally published on this site ADC Therapeutics announced it partnered with Freenome to identify biomarkers that can help to predict which diffuse large B-cell lymphoma (DLBCL) patients are most likely to respond to ADCT-402 (loncastuximab tesirine), its investigational antibody-drug conjugate now in a Phase 2 trial. Freenome has developed a platform that detects…
Real Awareness Means Understanding What Cancer Patients Experience
This post was originally published on this site We’re right in the middle of Lymphoma Awareness Month. I’ve always had kind of a funny relationship with it. It seems silly to remind me to be aware of something that is such a part of who I am. And as a follicular lymphoma advocate who reads…
Nanotechnology May Help Get Immunotherapy Into the Brain, Mouse Study Says
This post was originally published on this site Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune checkpoint inhibitors to enter the brains of mice with glioblastoma. The approach increased the amount of immune cells…
FDA to Review Nerlynx Combo as Third-line Treatment for HER2-positive Metastatic Breast Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has agreed to review Puma Biotechnology’s application seeking approval of Nerlynx (neratinib), in combination with capecitabine, to treat HER2-positive breast cancer patients with metastatic disease, the company has announced. The supplemental New Drug Application (sNDA) is for women who have failed two or…
Landmarks Lit in Blue in Every US State to Launch Prostate Cancer Awareness Month
This post was originally published on this site For the first time, landmarks in all 50 U.S. states were illuminated in blue on Sept. 3 to launch Prostate Cancer Awareness Month. The Prostate Cancer Foundation‘s “Light It Blue” effort is aimed at heightening disease awareness, supporting patients, and encouraging action. More than 174,000 men will…
Opdivo-Adcetris Combo Shows Promise in Advanced PMBL Patients in Trial
This post was originally published on this site Combining Opdivo (nivolumab) with Adcetris (brentuximab vedotin) could be a promising option for people with advanced primary mediastinal B-cell lymphoma (PMBL), an aggressive and hard-to-treat disease, results from the CheckMate-436 trial show. About 70% of the patients responded to this combination, and the lymphoma completely disappeared in…
Music Helps Ease Pain and Fatigue of Breast Cancer, Study Shows
This post was originally published on this site Listening to music at home can considerably ease the severity of symptoms related to breast cancer and its treatments, helping reduce the pain and fatigue patients experience, a trial reports. It found that setting time aside nearly every day for music significantly lessened patients’ intensity of pain and…